| Name | Rufinamide |
| Description | Rufinamide (E 2080), a triazole derivative, is used as voltage-gated sodium channel blocker for the treatment of seizure disorders. |
| In vitro | Rufinamide effectively suppresses maximal electroshock (MES)-induced tonic convulsions in mice (ED50 = 23.9 mg/kg) and rats (ED50 = 6.1 mg/kg). Additionally, Rufinamide inhibits pentylenetetrazol-(ED 50=54.0), bicuculline-(ED 50=50.5), and picrotoxin (ED 50=76.3 mg/kg) provoked clonic seizures in mice. Furthermore, it prevents pentylenetetrazole-induced epileptic seizures in mice at an effective dose of 45.8 mg/kg (ED50). |
| In vivo | Rufinamide inhibits sodium-dependent action potentials in neurons, potentially exhibiting membrane stabilizing effects. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 16.67 mg/mL (69.99 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 1.5 mg/mL (6.3 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | SodiumChannel | Sodium Channel | Rufinamide | RUF-331 | RUF331 | Inhibitor | inhibit | E-2080 | E2080 | CGP-33101 | CGP33101 |
| Inhibitors Related | Phenytoin sodium | Procaine | Ranolazine dihydrochloride | Tetracaine hydrochloride | Lidocaine | Safinamide | Permethrin | Valproic Acid | L-Aspartic aicd sodium | Lidocaine hydrochloride | Mebeverine hydrochloride | Dibucaine |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |